Brief: Annovis Bio Announces Patient Enrollment Update For Phase 3 Study Of Buntanetap For The Treatment Of Parkinson's Disease
25/01/2023 12:32
Jan 25 (Reuters) - Annovis Bio Inc ANVS.N :
* ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE
3
STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE
Source text for Eikon: ID:nPnwM7lFa
Further company coverage: ANVS.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman